Colchicine in Stable Coronary Artery Disease

Area of Science:

• Cardiology
• Pharmacology
• Inflammation

Background:

• Stable coronary artery disease (CAD) management focuses on hemostasis and lipids, lacking strategies to prevent plaque erosion or rupture.
• Cholesterol crystal-induced inflammation is a key factor in plaque destabilization, suggesting anti-inflammatory drugs as a potential treatment.
• Colchicine possesses anti-inflammatory properties that may target direct and indirect inflammatory mechanisms within atherosclerotic plaques.

Purpose of the Study:

• To review current literature and ongoing clinical trials on colchicine's efficacy in stable coronary artery disease (CAD).
• To assess the potential of colchicine as a therapeutic agent for secondary prevention in CAD by targeting inflammation.

Main Methods:

• A comprehensive literature search was conducted across major databases (MEDLINE, EMBASE, Cochrane) and clinical trial registries.
• The search focused on identifying completed and ongoing clinical studies investigating colchicine in patients with stable coronary artery disease.

Main Results:

• Preclinical studies and retrospective gout patient data suggest colchicine may reduce myocardial infarction size and restenosis.
• One prospective randomized trial indicated a potential protective effect of colchicine in stable CAD.
• Meta-analyses show a decrease in myocardial infarction with colchicine use across various cardiovascular diseases.
• Five major clinical trials (>10,000 patients) are currently recruiting to evaluate colchicine's impact on major cardiovascular outcomes.

Conclusions:

• Evidence on colchicine's efficacy for secondary prevention in stable and acute CAD is rapidly expanding.
• Colchicine's anti-inflammatory action may improve event-free cardiovascular survival.
• If proven effective, colchicine could become a third major pillar in stable CAD management, alongside lipid regulation and platelet inhibition.